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Editorial

Drug resistant tuberculosis: Challenges of
urbanization

The latest Global tuberculosis (TB) report indicates a sombre 8.6 million (range, 8.3–9.0 million) incident cases of TB in
2012. It further reports 1.3 million (range, 1.0–1.4 million)
deaths from TB during the course of 2012. While these figures
are extremely concerning, there is room for optimism. The
absolute number of TB cases worldwide is coming down. TB
prevalence has dropped from over 250/100,000 in 1990 to
169/100,000 in 2012, and TB mortality rates decreased by
45% since 1990 [1].
Despite these successes, TB control programs continue to
face major challenges. Significant threat has been posed by
Mycobacterium tuberculosis (M.tb) strains resistant to more than
one drug; in particular, multidrug resistant TB (MDR-TB) and
extensively drug resistant TB (XDR-TB). In 2012, there were
an estimated 450,000 incident cases of MDR-TB. The overall
proportion of MDR-TB cases with XDR-TB is estimated to be
9.6%, although a rate of more than 10% is documented in
some regions [1].
MDR-TB resistant to at least isoniazid (INH) and rifampicin
(RIF), the most effective anti-TB drugs, does not respond to
the standard six-month treatment with first-line anti-TB
drugs and requires a combination therapy, including second-line drugs that are less potent, more toxic and much
more expensive. Current guidelines advocate treatment duration of at least 20 months in patients without previous MDRTB treatment, and longer (28 to 30 months) in patients who
have previously been treated for MDR-TB. Despite second-line
treatment, the relative risk of dying from MDR-TB as compared with TB cases without MDR-TB is estimated at 2.36
(range 1.67–3.05). It is estimated that globally in 2012 there
were 170,000 deaths (range 100,000–240,000) from MDR-TB,
and only 48% of MDR-TB patients in the 2010 cohort were successfully treated [1].
Treatment of XDR-TB caused by strains that are resistant
to isoniazid and rifampicin (i.e. MDR-TB) as well as to fluoroquinolone and to any of the second-line anti-TB injectable
drugs (amikacin, kanamycin or capreomycin) is even more
difficult, complicated and associated with poor treatment
success rate [2,3]. Recently published outcome data on XDRTB from South Africa reports only 16% favourable outcome
(treatment cure or completion) and a mortality rate of 46%
at 2 years. The study further reports that by 5 years the per-

centage of patients showing a favourable outcome had
dropped to 11% and the mortality rate increased to 73% [4].
In addition to M/XDR-TB tuberculosis control is further
threatened by strains with additional resistance; Totally
Drug–Resistant Tuberculosis (TDR-TB) caused by strains
showing in-vitro resistance to all first and second line drugs
tested (isoniazid, rifampicin, streptomycin, ethambutol, pyrazinamide, ethionamide, para-aminosalicylic acid, cycloserine,
ofloxacin, amikacin, ciprofloxacin, capreomycin, kanamycin)
[5–8]. To date these strains are reported as being virtually
untreatable [8].
As part of the effort to reduce generation and spread of DRTB (drug resistant-tuberculosis) early recognition and supervised treatment of all TB patients is advocated. Additional
areas emphasised for control of DR-TB include: strengthening
diagnostic capacity for detection of drug resistant strains,
increasing access for treatment of DR-TB, and a greater focus
on HIV patients who are at a high risk of DR-TB. Control of
DR-TB however is difficult without emphasis on steps aimed
at reducing transmission of MDR-TB and XDR-TB strains
[9,10]. Hence infection-control practices in both community
and health care facilities are key elements of such a program.
Although introducing infection control measures may prove a
challenge in many high burden regions. Mathematical and
experimental models suggest that in health care settings facial
masks and improved ventilation could significantly reduce
transmission of DR-TB cases [11–13]. Similarly poor living environment including poor ventilation in the homes of DR-TB patients is also likely to contribute to disease transmission.
As a consequence of increasing globalization, there is
increasing urbanization. By 2010 urban outnumbered rural
populations. It is expected that by 2025 more than half of
the world’s citizens will be living in urban settings, with dozens of megacities characterized by populations of over 10 million persons. It is estimated that by the middle of the century,
out of every 10 people, 7 will be living in urban areas [14,15].
Moreover, it is estimated that, between 2010 and 2015, on
average 200,000 people will be added to the world’s urban
population every day. Of this daily increase, 91% (183,000) is
expected to take place in developing countries [15]. The urban
population in Africa is likely to triple, and in Asia to more
than double by 2050 [16].
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In low-income countries, economic growth does not keep
up with urbanization, and governments lack resources to
manage rapid urban expansion or to cope with increasing
influx of migrants [16]. In 2001, 924 million urban residents
lived in slums and informal settlements. This number is expected to double to almost 2 billion by 2030 [17]. Such slums
and informal settlements arising as a result of rapid and unplanned urbanization provide ideal conditions for transmission of infectious diseases, including TB and drug-resistant
TB. Densification and substandard housing with little sunlight and poor ventilation that characterize slum dwelling
[18] are well-recognised to contribute to transmission of TB
[19,20]. High prevalence of TB has been shown in urban
slums of Karachi and Dhaka [21,22]. Urban and peri-urban
dwelling has also been associated with higher risk MDR-TB
[23–25]. In view of such evidence, development and
implementation of national policies directed at controlling
the spread of TB and M/XDR-TB within the community
become essential.
Organizations and agencies involved in control of the
diseases must adapt to trends in population, growth and
urbanization and the changing global landscape [26]. As
such, efforts of TB control programs and the TB
community currently focused on diagnosis and treatment
needs to be expanded to include advocacy and regulations
for safe housing aimed at reducing transmission risk at a
community level.
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